Soligenix Advances Rare Disease Pipeline with Orphan Drug Designation and Phase 3 Trial Milestones in 2025 Results

Soligenix reported 2025 results highlighting progress in its Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphoma, with interim analysis expected in Q2 2026 and top-line results in H2. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behcet's Disease and a year-end cash position of approximately $7.9 million. Soligenix continues to pursue strategic options to support late-stage development.